DoD Spinal Cord Injury, Translational Research Award | W81XWH 21 SCIRP TRA

Opportunity Information: Apply for W81XWH 21 SCIRP TRA

The Department of Defense Spinal Cord Injury Research Program (SCIRP) Translational Research Award (TRA) is a discretionary funding opportunity run through the U.S. Army Medical Research Acquisition Activity (USAMRAA) that aims to push promising spinal cord injury (SCI) discoveries closer to real-world clinical use. The central purpose is to fund translational research projects that do more than explore basic mechanisms; they should actively accelerate the path from an observation or prototype to a clinical application that could improve care for people with SCI. In practice, this means studies designed to generate the kind of evidence needed to justify and inform the next stage of development, such as readiness for a first-in-human study, refinement of a device or therapy for clinical testing, or clinical research that changes how an intervention is used or evaluated.

The opportunity explicitly frames “translational” as broader than a simple bench-to-bedside pipeline. Applicants are encouraged to build a plan that supports two-way learning between laboratory and clinical settings, where insights from patients, clinicians, and human-based resources can shape the preclinical work, and where preclinical findings can directly guide clinical approaches. The program description gives representative examples of the kinds of projects that may fit: demonstration studies of pharmaceuticals or medical devices in preclinical systems, and clinical research on therapeutics, devices, or clinical practices that uses human tissues, human data, or other human resources. Across these examples, the emphasis is on producing actionable results that reduce uncertainty and speed clinical introduction of healthcare products, enabling technologies, or practice guidelines.

A key requirement is that applications must be grounded in relevant evidence. Proposals need to include preliminary and/or published data that relate to SCI and directly support the feasibility and rationale of the proposed work. In other words, this award is not intended for purely exploratory ideas without supporting data; it is meant for concepts that already have traction and can reasonably be advanced toward clinical impact within the scope of the project.

Another defining feature is the expectation that applicants clearly map their project onto the translational spectrum by addressing three specific points. First, they must explain where the field currently stands (the present state of knowledge, capability, or unmet need). Second, they must describe where the field will be after the project is successfully completed (the concrete advance their results will deliver, such as validated proof-of-concept, improved safety or performance data, a clinically usable protocol, or evidence supporting a subsequent trial). Third, they must state what the next step will be once the project ends (for example, the specific follow-on preclinical milestone, regulatory step, clinical trial phase, commercialization pathway, or implementation study that their results will enable). This structure is designed to ensure the work is not only scientifically sound but also positioned to continue moving forward toward patient benefit.

The work must also be relevant to the Department of Defense community and the broader public, meaning it should have clear applicability to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. This relevance criterion is important because it ties the scientific goals to real populations affected by SCI, including injuries and long-term complications that may be especially pertinent to military and veteran health.

Administratively, the funding opportunity is identified as W81XWH 21 SCIRP TRA and is offered as either a grant or a cooperative agreement under CFDA 12.420, within the Science and Technology and other Research and Development activity category. Eligibility is described as unrestricted (open to any type of applicant entity, subject to any additional eligibility clarifications in the full announcement). The posting indicates an expected number of awards of five. The listing also shows an award ceiling of 0, which typically signals that applicants need to consult the full funding announcement for budget constraints or that the ceiling is not specified in the summary record. The opportunity was created on March 29, 2021, with an original closing date of September 3, 2021.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Spinal Cord Injury, Translational Research Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 29, 2021.
• Applicants must submit their applications by Sep 03, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 SCIRP TRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: